Avoid common mistakes on your manuscript.
Retraction Note: Drug Delivery and Translational Research (2018) 9:37-52 https://doi.org/10.1007/s13346-018-0575-8
The Editor-in-Chief has retracted this article at the authors' request. After publication, concerns were raised regarding the figures published in this article. Specifically:
-
In Fig. 5b, the blue signal in the DAPI and MERGED columns do not appear to match.
-
In Fig. 6, the Control plot appears to be missing some data points; the HA-PCL-CAP % values don't appear to match the data point distribution.
-
In Fig. 9, the Normal and CAP group images appear to originate from the same sample with different magnification.
-
The western blots in Fig. 11a contained splice marks and highly similar bands. This was addressed by a correction [1]. However, the blots in the correction don't match the data presented in the bar graphs for Bax and casp-9.
Additionally, the study does not appear to adhere to the journal's animal ethics requirements. The authors have not commented on any of these concerns. The Editor-in-Chief therefore no longer has confidence in the presented data.
None of the authors have responded to any correspondence from the editor or publisher about this retraction.
Reference
Parashar P, Tripathi CB, Arya M, et al. Correction to: a facile approach for fabricating CD44-targeted delivery of hyaluronic acid-functionalized PCL nanoparticles in urethane-induced lung cancer: Bcl-2, MMP-9, caspase-9, and BAX as potential markers. Drug Deliv and Transl Res. 2020;10:1532–3. https://doi.org/10.1007/s13346-020-00783-8.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Parashar, P., Tripathi, C.B., Arya, M. et al. Retraction Note: A facile approach for fabricating CD44-targeted delivery of hyaluronic acid-functionalized PCL nanoparticles in urethane-induced lung cancer: Bcl-2, MMP-9, caspase-9, and BAX as potential markers. Drug Deliv. and Transl. Res. 13, 2425 (2023). https://doi.org/10.1007/s13346-023-01354-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13346-023-01354-3